Peer Exchange

Current Considerations in Managing Hyperhidrosis
June 29, 2018 – 
Shawn Davis, PharmD, defines hyperhidrosis and remarks on current limitations in recognizing it as a clinical condition.
Types of Hyperhidrosis
June 29, 2018 – 
Dee Anna Glaser, MD; Adelaide Hebert, MD; and Adam Friedman, MD, FAAD, outline the signs and symptoms of hyperhidrosis and differentiate between the primary focal and secondary generalized types.
Determining Cost-Effectiveness of Newer HIV Therapies
April 02, 2018 – 
Michael G. Sension, MD; Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; and Elly Fatehi, PharmD, MPH, offer their perspectives on the challenges with determining the cost effectiveness of newer HIV therapies versus existing therapies.
Emerging Therapies in HIV
March 26, 2018 – 
Peter L. Salgo, MD; Michael G. Sension, MD; Jeffrey D. Dunn, PharmD, MBA; and Elly Fatehi, PharmD, MPH, discuss emerging therapies in HIV and the impact that effective therapies have had on sense of urgency.
Collaborative Approach in Managing HIV Treatment Costs
March 26, 2018 – 
Peter L. Salgo, MD; Michael G. Sension, MD; Elly Fatehi, PharmD, MPH; and Jeffrey D. Dunn, PharmD, MBA, examine the potential for collaboration among payers and providers to achieve good clinical outcomes in HIV treatment that are cost effective.
HIV Therapy Utilization Management Concerns
March 19, 2018 – 
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, offer insight regarding the potential impact that tighter management of HIV agents would have on clinical decision making.
Formulary Decision-Making Challenges in HIV
March 19, 2018 – 
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, discuss the challenges with payer management of HIV therapies.
Balancing Cost and Physician Choice in HIV
March 12, 2018 – 
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, discuss the difficulty in finding a common ground with clinical decision making and cost control for HIV therapies.
HIV Medication Adherence and Resistance Development
March 12, 2018 – 
Peter L. Salgo, MD; Elly Fatehi, PharmD, MPH; Jeffrey D. Dunn, PharmD, MBA; and Michael G. Sension, MD, discuss the connection between poor compliance and development of resistance in patients with HIV.
Nuances of HIV Treatment
March 05, 2018 – 
Peter L. Salgo, MD; Elly Fatehi, PharmD, BCPS; Michael Sension, MD; and Jeffrey Dunn, PharmD, explore scenarios that require HIV treatments that fall outside of the guideline recommendations for most patients.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!